There is a small, but real, increase in stroke with radial access that should prompt caution, says Ian Gilchrist.

The gap in care shown by statewide data substantiate certain biases among cardiothoracic surgeons, says Armin Kiankhooy.

More robust data are needed to improve estimates and ensure adequate statistical power for trials, a researcher says.

Only when the Fourth Universal Definition of MI was adjudicated with two or more clinical criteria was it prognostically ...

With the approval of mavacamten, patients with hypertrophic cardiomyopathy now have more options, Steve Ommen says.

In a letter to providers, the FDA advises using alternatives, if possible, saying the company has not fully addressed ...

The progression of atherosclerosis, at a cellular level, is reminiscent of the processes involved in tumor growth, new ...

As a slew of new catheter-based devices hit the market, it will be crucial to keep tabs on eligibility, safety, and access, ...

If the LV is likely to improve or normalize with TAVI, there’s no reason not to treat, says Guy Witberg. But for some TAVI ...

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company's ...

Even at a mean age of 85 years, there is still time to accrue mortality benefits from potent LDL-lowering therapies.

Procedural complications and short-term mortality were higher with concomitant procedures, but mortality to 3 years was not.